MedTrace Logo

Observational Study of Ultravist in Patients Requiring CECT

NCT01415414 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11660

Last updated 2015-01-21

No results posted yet for this study

Summary

It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.

Conditions

  • Diagnostic Imaging

Interventions

DRUG

Iopromide (Ultravist, BAY86-4877)

CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-07-31
Completion
2013-11-30

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415414 on ClinicalTrials.gov